NCT06232122 Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
| NCT ID | NCT06232122 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chang Gung Memorial Hospital |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2022-08-01 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2022-08-01 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy
Eligibility Criteria
Inclusion Criteria: * Pathologically proven ovarian cancer with complete response after therapy * Age between 30 and 80 * Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range * ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed * Willing to enter this prospective study with signed informed consent form Exclusion Criteria: * Patients with history of other malignancy * Patients who are pregnant or lactating * Patients with fasting fingerstick glucose level higher than 200 mg/dl * Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies * Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06232122 clinical trial?
This trial is open to female participants only, aged 30 Years or older, up to 80 Years, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06232122 currently recruiting?
Yes, NCT06232122 is actively recruiting participants. Contact the research team at billliu@cgmh.org.tw for enrollment information.
Where is the NCT06232122 trial being conducted?
This trial is being conducted at Taoyuan City, Taiwan.
Who is sponsoring the NCT06232122 clinical trial?
NCT06232122 is sponsored by Chang Gung Memorial Hospital. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.